Harnessing the innate mechanism of gene activation

MiNA Therapeutics is a clinical-stage biotechnology company specializing in RNA activation therapeutics with an initial focus on liver cancer (hepatocellular carcinoma). MiNA’s platform enables the development of new medicines that restore normal function to patients’ cells by harnessing an innate mechanism of gene activation. The Company is focused on developing short activating RNA (saRNA), a new mode of RNA therapies that can activate protein production in targeted cells. MiNA’s lead clinical product targets myeloid derived suppressor cells (MDSC), an important target in solid tumors that has been shown to interfere with the body’s immune response to cancer. Early clinical data has demonstrated potentially promising results in hepatocellular carcinoma.

Leadership:

Investing partner / fund: